1. Home
  2. EVAX vs BCDA Comparison

EVAX vs BCDA Comparison

Compare EVAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • BCDA
  • Stock Information
  • Founded
  • EVAX 2008
  • BCDA N/A
  • Country
  • EVAX Denmark
  • BCDA United States
  • Employees
  • EVAX N/A
  • BCDA N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • BCDA Health Care
  • Exchange
  • EVAX Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • EVAX 17.8M
  • BCDA 11.3M
  • IPO Year
  • EVAX 2021
  • BCDA N/A
  • Fundamental
  • Price
  • EVAX $2.90
  • BCDA $2.16
  • Analyst Decision
  • EVAX Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • EVAX 2
  • BCDA 1
  • Target Price
  • EVAX $10.00
  • BCDA $25.00
  • AVG Volume (30 Days)
  • EVAX 89.0K
  • BCDA 39.6K
  • Earning Date
  • EVAX 10-30-2025
  • BCDA 11-12-2025
  • Dividend Yield
  • EVAX N/A
  • BCDA N/A
  • EPS Growth
  • EVAX N/A
  • BCDA N/A
  • EPS
  • EVAX N/A
  • BCDA N/A
  • Revenue
  • EVAX $3,176,000.00
  • BCDA N/A
  • Revenue This Year
  • EVAX N/A
  • BCDA N/A
  • Revenue Next Year
  • EVAX N/A
  • BCDA N/A
  • P/E Ratio
  • EVAX N/A
  • BCDA N/A
  • Revenue Growth
  • EVAX 1042.45
  • BCDA N/A
  • 52 Week Low
  • EVAX $1.20
  • BCDA $1.63
  • 52 Week High
  • EVAX $17.20
  • BCDA $3.25
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 50.88
  • BCDA 59.02
  • Support Level
  • EVAX $2.71
  • BCDA $2.11
  • Resistance Level
  • EVAX $3.04
  • BCDA $2.29
  • Average True Range (ATR)
  • EVAX 0.20
  • BCDA 0.09
  • MACD
  • EVAX -0.01
  • BCDA 0.03
  • Stochastic Oscillator
  • EVAX 55.97
  • BCDA 66.67

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: